This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Strongbridge Biopharma (SBBP) Rises: Stock Moves 17% Higher
by Zacks Equity Research
Strongbridge Biopharma plc (SBBP) shares rose almost 17% in the last trading session.
Dr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise
by Zacks Equity Research
Dr. Reddy's Laboratories Ltd.'s (RDY) first-quarter fiscal 2018 earnings per American Depositary Share (ADS) declined year over year while sales increased from the year ago quarter.
Acorda (ACOR) Q2 Earnings Miss Estimates, Revenues in Line
by Zacks Equity Research
Acorda's (ACOR) dismal performance in Q2 significantly misses earnings expectations. However, the company's revenues met estimates on the back of strong Ampyra sales.
Keryx (KERX) Posts Wider than Expected Loss in Q2, Sales Beat
by Zacks Equity Research
Keryx's (KERX) loss in Q2 was wider than expected but sales beat estimates. The company also raised its 2017 outlook for net U.S. Auryxia product sales.
Alkermes (ALKS) Q2 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Alkermes plc (ALKS) incurred narrower than expected loss in Q2 but marginally surpassed sales estimates. The company reiterated its 2017 outlook.
Bayer (BAYRY) Q2 Earnings Beat, Sales Miss, Cuts Guidance
by Zacks Equity Research
Bayer AG (BAYRY) topped earnings but missed sales expectations in Q2. The company also lowered its guidance for full-year 2017.
GlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance
by Zacks Equity Research
Glaxo's (GSK) second-quarter earnings beat estimates, while revenues miss the same. The company cuts its core 2017 earnings growth at CER, with no Advair generics launched this year.
Alexion (ALXN) Tops Q2 Earnings & Revenues, Ups 2017 View
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) exceeded both earnings and revenue estimates in Q2 and also raised its 2017 guidance.
Ironwood (IRWD) Reports Positive Data on Reflux Candidate
by Zacks Equity Research
Ironwood's GI candidate met the primary endpoint of a phase IIb study. It showed significant reduction in weekly heartburn severity in adult patients with reflux disease.
Galapagos (GLPG) Looks Good: Stock Adds 6.2% in Session
by Zacks Equity Research
Galapagos (GLPG) was a big mover last session, as the company saw its shares rise over 6% on the day.
Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab
by Zacks Equity Research
Emergent's shares inched up post announcement of its deal inked with GlaxoSmithKline to acquire the latter's anthrax monoclonal antibody raxibacumab.
Sarepta & BioMarin Settle Patent Litigation on Exon Skipping
by Zacks Equity Research
Sarepta Therapeutics, Inc. (SRPT), and BioMarin Pharmaceutical Inc., have settled their ongoing global patent litigation pertaining to exon skipping technology used in Duchenne muscular dystrophy therapies.
Vertex (VRTX) Triple Combination CF Studies Data Positive
by Zacks Equity Research
Vertex announced positive data from three studies evaluating three different triple combination regimens. These demonstrated pronounced improvements in lung function in CF patients.
Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt
by Zacks Equity Research
Valeant (VRX) has decided to sell Obagi Medical for $190 million and use the proceeds for reducing down debt.
Repros' Proellex Stays on Partial Clinical Hold, Shares Fall
by Zacks Equity Research
Repros Therapeutics Inc. (RPRX) announced that its pipeline candidate Proellex which is being evaluated for uterine fibroids will remain on partial clinical hold.
Arena Announces Secondary Stock Worth $150M (revised)
by Zacks Equity Research
Arena plans to offer and sell shares of its common stock worth $150 million, subject to customary closing conditions.
Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit
by Zacks Equity Research
Emergent BioSolutions Inc. (EBS) announced that it has inked an agreement to acquire the FDA-licensed smallpox vaccine's business of Sanofi (SNY) in an all-cash deal of up to $125 million.
Can Enzo Biochem (ENZ) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
Enzo Biochem (ENZ) is seeing solid earnings estimate revisions, and the stock is showing decent short-term momentum as well.
Gemphire Therapeutics (GEMP) Catches Eye: Stock Gains 9.7%
by Zacks Equity Research
Gemphire Therapeutics Inc. (GEMP) moved big last session, as its shares rose over 9% on the day.
BioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) announced an exclusive partnership agreement with Purdue Pharma, a Canadian pharmaceutical company, for commercializing its pain drug Belbuca in Canada.
Mallinckrodt's MNK-1411 Gets Orphan Drug Status for DMD
by Zacks Equity Research
Mallinckrodt plc (MNK) announced that the FDA has granted orphan drug designation to its pipeline candidate - MNK-1411, which is being evaluated for the treatment of Duchenne muscular dystrophy (DMD).
Corcept Therapeutics Focuses on Korlym's Label Expansion
by Zacks Equity Research
We issued an updated research report on Corcept Therapeutics Incorporated (CORT) on Jul 12.
Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform
by Zacks Equity Research
We issued an updated research report Endocyte, Inc. (ECYT) on Jul 12.
Mallinckrodt to Pay $35M for Controlled Substances Probe
by Zacks Equity Research
Mallinckrodt plc (MNK) recently finalized the agreement which it had reached with the U.S. Drug Enforcement Administration (DEA) and the U.S. Attorneys' Offices (USAOs) for the Eastern District of Michigan and the Northern District of New York.
Arena Announces Secondary Stock Offering of 150M Shares
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) plans to offer and sell 150 million shares of its common stock, subject to customary closing conditions.